Key Takeaways
- Base business stabilizes post-Revlimid: With zero Revlimid contribution, H2 FY26 becomes the recurring earnings baseline, driven by emerging markets and subsidiaries. Management expects to meet FY26 revenue guidance of ~₹4,200–₹4,300 crores.
- GLP-1 is the near-term catalyst: Semaglutide (Ozempic) approval is expected this month, with launch shortly after March; the company holds sole first-to-file status on certain strengths and has already settled on Ozempic.
- Cash preserved for another large M&A: Management explicitly ruled out a buyback, preferring to reserve cash for a transaction similar in size to the Adcock acquisition, with 2–3 targets under active pursuit.
- eGenesis represents a high-risk, high-reward optionality: One patient dosed, another doing well; management calls it "the idea of the decade," with a home-run scenario if the trial reaches 25–30 patients in the next 2–3 years.
- What to watch next quarter: Semaglutide approval and launch timing, clarity on olaparib tentative approval and exclusivity, and progress on closing at least one large acquisition in calendar 2026.
GLP-1 & India Growth
- Approval imminent: GLP-1 approval is pending at DCGI and expected sometime in February 2026; the Ozempic clinical trial is complete and SEZ committee clearance has been received, with a license expected any moment.
- Dual application strategy: The company has filed for both generic Ozempic (diabetes) and generic Wegovy (obesity); the Wegovy clinical trial is expected to complete soon, after which the company will file for approval.
- Sole FTF on key strengths: Certain strengths of both Ozempic and Wegovy carry sole first-to-file status, covering a significant part of the market; Ozempic is already settled, while Wegovy is not yet settled.
- India launch dynamics: The diabetes strength (Ozempic) is expected to launch when the market opens up shortly after March; management expects the Indian semaglutide market to be extremely competitive with many generics entering.
- Capacity constraint acknowledged: The company currently outsources fill-and-finish to OneSource and has no owned capacity; management declined to share reserved capacity, citing uncertainty around demand.
Rajeev Nannapaneni: "India is actually a very tricky market. I'm positive about the semaglutide launch, but I think it will be extremely competitive. I think my expectation is that there are going to be a lot of generics."
Base Business & Diversification
- H2 FY26 sets the recurring baseline: With no Revlimid contribution in the second half, the current run-rate represents the base business going forward; any new launches will be incremental on top of this.
- Emerging markets are the earnings anchor: Base earnings are largely coming from the Middle East, Brazil, and Canada; Brazil has strong approvals expected this year, and management is very bullish on emerging markets as the growth driver.
- Diversification thesis playing out: Over the last 3–4 years, the company has diversified its profit base, bringing more stability; despite the Revlimid cliff, the company delivered reasonable earnings.
- Adcock pipeline build underway: Adcock's base business has been flat, but NATCO's pipeline input (oncology, GLP-1, HIV) will strengthen it; real earnings value is expected in approximately 2 years once registrations start, with growth visible in 18–24 months.
- R&D spend front-loaded: Other expenses declined sequentially and YoY because a large portion of the R&D budget allocation and one-time bonuses were completed in the September quarter, anticipating the Revlimid decline.
Para IV Pipeline & U.S. Launches
- Erdafitinib approval secured: The company received U.S. approval for erdafitinib as the first generic via a Para IV filing; litigation is still ongoing, and management called any launch timeline discussion premature.
- Olaparib settlement with shared exclusivity: A settlement has been reached in the U.S.; the company holds shared exclusivity on the 60-mg strength and sole exclusivity on one other strength; the launch date is bound by confidentiality, with clarity expected in the next few months.
- Niraparib filed but not FTF: The company filed niraparib, a complex cancer product requiring patient bioequivalence studies, but another company beat them to first-to-file status by a few months.
- Non-Para IV ANDA launches near: Approvals for non-Para IV ANDAs are expected in the next few months, with launches anticipated in the April–June quarter; some older products are being launched pending FDA approval and manufacturing equipment adjustments.
- Complex generic filing momentum: The company targets filing approximately 8 complex generic products this year, with 4–5 already filed; management expects something to hit in the next 12 months.
- Long-dated Para IV pipeline: Multiple Para IV launches are expected over a period stretching from 2026 to 2035.
M&A & Capital Allocation
- Cash reserved for a large transaction: Management explicitly ruled out a buyback, stating a preference to preserve cash for another transaction similar in size to the Adcock acquisition.
- 2–3 targets under active pursuit: The company is actively pursuing acquisition targets focused on emerging markets and established brand businesses; management hopes to close at least 1 or 2 large transactions in calendar year 2026, subject to diligence clearance.
- Returns outside India preferred: Management believes returns on capital outside India are much better than domestic opportunities, acknowledging this goes against conventional thinking that favors the more certain and controllable Indian environment.
- Scale requires M&A plus pipeline: Management argued that achieving disruptive scale in India purely organically would require destructive pricing that destroys value for everyone; the only viable path is combining pipeline with M&A.
- Funding mix for large deals: For a very large acquisition, the company would use a mix of debt, equity, and internal cash flow.
- Adcock shareholding increase possible: The company can increase its stake in Adcock subject to Bidvest's willingness to sell; Bidvest has not shown interest so far, but the agreement permits an increase if they become interested.
Rajeev Nannapaneni: "I would like to preserve my cash for another transaction similar to size of Adcock. I wouldn't want to do a buyback at this time."
eGenesis & NCE Optionality
- eGenesis progressing with mixed results: One patient who received a transplanted kidney had it removed after 6 months, but another patient is doing extremely well; the company is trying to extend the trial to multiple patients.
- Home-run scenario defined: If the trial reaches a stage demonstrating about 25–30 patients, management considers it a home run, with this outcome potentially playing out in the next 2–3 years.
- NCE pipeline early-stage: The company has 5 NCE ideas in the pipeline, but management declined to provide specific quantification or timelines for individual molecules when asked.
Rajeev Nannapaneni: "This is probably the most disruptive thing that's going to happen in medicine... If you ask me, this is an idea of the decade."
Regulatory & Operational Updates
- FDA plant status largely clean: The Kothur warning letter has been removed; Mekaguda was inspected and cleared; the Chennai facility was inspected this year with procedural observations, and classification is expected in 30–40 days; the Vizag formulation facility is due for inspection, having gone approximately 2.5–3 years since its last inspection.
- Crop Health Sciences de-merger underway: The process has started with a goal to complete in the next 8–9 months, roughly by October/November, though management cautioned the process will take whatever time it requires.
- Adcock amortization modest: Annual amortization related to the Adcock acquisition is expected to be approximately INR10–14 crores per year, or roughly INR3 crores per quarter, though accountants are still finalizing the figure.
- R&D partnership model returning: For complex generics, the company plans to split R&D expenditure with partners to reduce risk, reverting to NATCO's original model of sharing costs on strong Para IV ideas.
Rajeev Nannapaneni: "I think the returns outside India are much better than India. I think that has always been my take. And I mean, obviously, I've been against the grain in the conventional thinking that people have been more comfortable doing acquisitions within India because it's a more certain environment and the variables are more controllable. But having said that, I believe that going out, the return is much higher."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 revenue | ~₹4,200–₹4,300 crores, with Q4 at ₹700–₹750 crores | FY26 (March 2026) |
| FY26 PAT | ~₹1,280–₹1,300 crores based on 9-month PAT of ~₹1,150 crores | FY26 (March 2026) |
| GLP-1 (Ozempic) approval | Pending at DCGI, SEZ clearance received | February 2026 |
| GLP-1 (Ozempic) launch | Diabetes strength launch when market opens | Post-March 2026 |
| Wegovy filing | Clinical trial completion, then filing for approval | Shortly (no date) |
| Crop Health Sciences de-merger | Process completion | 8–9 months (~Oct/Nov 2026) |
| Large M&A closure | At least 1–2 large transactions | Calendar year 2026 |
| Non-Para IV ANDA launches | Approvals expected, launches to follow | April–June 2026 quarter |
| Complex generic filings | ~8 products targeted, 4–5 already filed | FY26 |
| eGenesis home-run scenario | Trial reaches ~25–30 patients | Next 2–3 years |
| Olaparib clarity | Tentative approval and exclusivity details | Next few months |
| Semaglutide market guidance | More clarity on uptake and guidance | May 2026 (annual audited numbers) |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Consolidated total revenue | ₹705.4 cr, vs ₹651.1 cr in Q3 FY25 |
| EBITDA | ₹216.8 cr, margin at 30.7% |
| Net profit (consolidated) | ₹151.3 cr |
| Revenue from Adcock Ingram (H1 FY26) | ₹2,464 cr, profit after tax of ₹198 cr |
| Adcock profit share reflected in NATCO books | ₹10.9 cr, after one-time amortization of ₹18.75 cr on ₹29.65 cr profit pick-up at 35.75% |
| Net cash position | ~₹2,500 cr |
| Interim dividend | ₹1.5 per equity share of ₹2 face value |
| Revlimid revenue | ₹0, no Revlimid in the quarter |
| Export formulations YoY uptick | ~₹135 cr |
| Subsidiary sales | ₹177 cr out of total ₹705 cr |
| R&D spend | ~8% of sales (rough estimate) |
| Total MR strength | ~600, with ~350–400 allocated to semaglutide |
| FY26 revenue guidance | ~₹4,200–₹4,300 cr, with 9M at ₹3,559 cr and Q4 expected at ₹700–₹750 cr |
| FY26 PAT guidance | ~₹1,280–₹1,300 cr, with 9M at ~₹1,150 cr and Q4 expected at ~₹150 cr |
| Annual Adcock amortization expected | ~₹10–₹14 cr per year, roughly ₹3 cr per quarter |